BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 29644387)

  • 1. Personalized cancer vaccines: adjuvants are important, too.
    Gouttefangeas C; Rammensee HG
    Cancer Immunol Immunother; 2018 Dec; 67(12):1911-1918. PubMed ID: 29644387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in personalized neoantigen vaccines for cancer immunotherapy.
    Sun C; Xu S
    Biosci Trends; 2020 Nov; 14(5):349-353. PubMed ID: 32908077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptide-based vaccines for cancer therapy.
    Parmiani G; Russo V; Maccalli C; Parolini D; Rizzo N; Maio M
    Hum Vaccin Immunother; 2014; 10(11):3175-8. PubMed ID: 25483658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colorectal cancer vaccines: Tumor-associated antigens
    Wagner S; Mullins CS; Linnebacher M
    World J Gastroenterol; 2018 Dec; 24(48):5418-5432. PubMed ID: 30622371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospect and progress of personalized peptide vaccinations for advanced cancers.
    Sakamoto S; Noguchi M; Yamada A; Itoh K; Sasada T
    Expert Opin Biol Ther; 2016; 16(5):689-98. PubMed ID: 26938083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine.
    Noguchi M; Sasada T; Itoh K
    Cancer Immunol Immunother; 2013 May; 62(5):919-29. PubMed ID: 23197273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy.
    Tiptiri-Kourpeti A; Spyridopoulou K; Pappa A; Chlichlia K
    Pharmacol Ther; 2016 Sep; 165():32-49. PubMed ID: 27235391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models.
    Zhang R; Yuan F; Shu Y; Tian Y; Zhou B; Yi L; Zhang X; Ding Z; Xu H; Yang L
    Cancer Immunol Immunother; 2020 Jan; 69(1):135-145. PubMed ID: 31807878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic cancer vaccines: From initial findings to prospects.
    Song Q; Zhang CD; Wu XH
    Immunol Lett; 2018 Apr; 196():11-21. PubMed ID: 29407608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Personalized peptide vaccine for cancer treatment; now and its future].
    Waki K; Yamada A
    Nihon Rinsho; 2017 Feb; 75(2):251-256. PubMed ID: 30562860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-cell epitope peptide vaccines.
    Elsawa SF; Rodeberg DA; Celis E
    Expert Rev Vaccines; 2004 Oct; 3(5):563-75. PubMed ID: 15485336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Peptide-based vaccine therapy for cancer patients].
    Yamada A
    Nihon Rinsho; 2005 Apr; 63 Suppl 4():602-7. PubMed ID: 15861717
    [No Abstract]   [Full Text] [Related]  

  • 13. The Changing Landscape of Therapeutic Cancer Vaccines-Novel Platforms and Neoantigen Identification.
    Jou J; Harrington KJ; Zocca MB; Ehrnrooth E; Cohen EEW
    Clin Cancer Res; 2021 Feb; 27(3):689-703. PubMed ID: 33122346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer vaccines. Any future?
    Myc LA; Gamian A; Myc A
    Arch Immunol Ther Exp (Warsz); 2011 Aug; 59(4):249-59. PubMed ID: 21644030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer immunotherapy-targeted glypican-3 or neoantigens.
    Shimizu Y; Suzuki T; Yoshikawa T; Tsuchiya N; Sawada Y; Endo I; Nakatsura T
    Cancer Sci; 2018 Mar; 109(3):531-541. PubMed ID: 29285841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer neoantigen: Boosting immunotherapy.
    Xu P; Luo H; Kong Y; Lai WF; Cui L; Zhu X
    Biomed Pharmacother; 2020 Nov; 131():110640. PubMed ID: 32836075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melanoma vaccines: mixed past, promising future.
    Ozao-Choy J; Lee DJ; Faries MB
    Surg Clin North Am; 2014 Oct; 94(5):1017-30, viii. PubMed ID: 25245965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Approaches to Improve Chemically Defined Synthetic Peptide Vaccines.
    Hos BJ; Tondini E; van Kasteren SI; Ossendorp F
    Front Immunol; 2018; 9():884. PubMed ID: 29755468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy.
    Seremet T; Brasseur F; Coulie PG
    Cancer J; 2011; 17(5):325-30. PubMed ID: 21952282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor vaccination using peptide based vaccines.
    Eisenbach L; Bar-Haim E; El-Shami K
    Immunol Lett; 2000 Sep; 74(1):27-34. PubMed ID: 10996624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.